Concord Biotech Limited (BOM:543960)

Concord Biotech Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	121.86	9.05	151.42	34.99	6.67
Short-Term Investments	-	176.33	179.89	228.22	305.8	872.5
Trading Asset Securities	-	4,021	3,165	2,437	1,369	734.73
Cash & Short-Term Investments	4,319	4,319	3,354	2,817	1,710	1,614
Cash Growth	35.93%	28.75%	19.09%	64.71%	5.96%	-19.76%
Accounts Receivable	-	4,602	5,217	3,496	2,738	2,322
Other Receivables	-	101.51	210.46	193.66	217.95	272.74
Receivables	-	4,703	5,427	3,690	2,956	2,594
Inventory	-	3,264	2,397	2,080	2,123	1,951
Prepaid Expenses	-	75.58	73.91	73.31	55.19	47.61
Other Current Assets	-	139.68	100.48	303.06	433.05	119.5
Total Current Assets	-	12,501	11,352	8,962	7,277	6,327
Property, Plant & Equipment	-	8,661	8,442	7,865	7,655	6,436
Long-Term Investments	-	891.72	347.62	20.7	79.25	2.56
Goodwill	-	3.96	-	-	-	-
Other Intangible Assets	-	14.25	11.22	3.2	1.98	35.77
Long-Term Deferred Tax Assets	-	29.37	-	-	-	-
Other Long-Term Assets	-	246.29	189.05	156.1	126.8	327.4
Total Assets	-	22,347	20,343	17,007	15,140	13,128

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	1,019	1,130	944.35	938	831.06
Accrued Expenses	-	230.24	192.07	168.21	146.19	131.45
Short-Term Debt	-	-	3.81	-	-	43.37
Current Portion of Long-Term Debt	-	-	-	62.3	250	250
Current Portion of Leases	-	8.82	19.58	16.21	1.47	15.96
Current Income Taxes Payable	-	0.09	101.27	54.94	89.99	-
Current Unearned Revenue	-	-	-	-	13.13	32.72
Other Current Liabilities	-	432.53	393.5	175.55	479.67	247.1
Total Current Liabilities	-	1,691	1,841	1,422	1,918	1,552
Long-Term Debt	-	-	-	-	62.36	312.49
Long-Term Leases	-	14.33	6.3	18.87	1.64	3.11
Long-Term Deferred Tax Liabilities	-	453.59	340.22	280.65	234.39	209.71
Other Long-Term Liabilities	-	37.2	28.2	19.56	22.97	18.74
Total Liabilities	-	2,196	2,215	1,741	2,240	2,096

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	104.62	104.62	104.62	104.62	95.11
Additional Paid-In Capital	-	819.71	819.71	819.71	819.71	829.22
Retained Earnings	-	19,250	17,203	14,342	11,976	10,108
Comprehensive Income & Other	-	-4.01	-	-	-	-
Total Common Equity	20,171	20,171	18,127	15,266	12,900	11,032
Minority Interest	-	-19.23	-	-	-	-
Shareholders' Equity	20,151	20,151	18,127	15,266	12,900	11,032
Total Liabilities & Equity	-	22,347	20,343	17,007	15,140	13,128

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	23.16	23.16	29.69	97.38	315.46	624.93
Net Cash (Debt)	4,296	4,296	3,325	2,719	1,395	988.98
Net Cash Growth	36.48%	29.20%	22.26%	94.98%	41.02%	-11.58%
Net Cash Per Share	40.93	41.06	31.78	25.99	13.33	9.45
Filing Date Shares Outstanding	106.03	104.62	104.62	104.62	104.62	104.62
Total Common Shares Outstanding	106.03	104.62	104.62	104.62	104.62	104.62
Working Capital	-	10,810	9,512	7,541	5,359	4,775
Book Value Per Share	192.81	192.81	173.27	145.93	123.31	105.45
Tangible Book Value	20,152	20,152	18,116	15,263	12,898	10,996
Tangible Book Value Per Share	192.63	192.63	173.17	145.90	123.29	105.11
Land	-	629.93	629.93	547.11	547.11	547.11
Buildings	-	3,732	3,553	2,576	2,463	2,226
Machinery	-	7,097	6,622	4,979	4,788	4,285
Construction In Progress	-	781.59	501.31	2,115	1,727	741.55

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 2, 2026

Data Sources Report a data error